Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
Status:
Suspended
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the
safety, tolerability and efficacy of S-1226 in which hospitalized subjects (n≤30) with
moderate severity COVID-19 Bronchiolitis/Pneumonia will be enrolled. The safety and
tolerability of S-1226 composed of PFOB with ascending doses of carbon dioxide (4%, 8%, and
12% CO2) administered twice daily will be assessed subjects in hospitalized subjects with
moderate severity COVID-19 Bronchiolitis/Pneumonia.